{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'leader listed below:', '1.2 Name and Description of IMP (Other sections affected by this change: 3.8.1, 3.13 [Table 1,', 'footnote \"y\"], 3.13.2, 3.13.3.1.1, 3.13.3.1.2, 3.13.3.2.1, 3.13.3.2.2, 3.13.5, 5.1, 11.4.1)', 'The IMP will be supplied in', 'The IMP will be supplied in 40-count', 'Blister pack IMP', '2040-count tablets per dose strength', 'blister packs', 'replacing bottled', 'per bottleblister packs', 'IMP for blinding', 'maintenance', 'purposes', '1.5.1 Justification for Dosage of Active Drug (Other section affected by this change: 3.1.3 and 5.1)', 'The dose ranges to be evaluated in this', 'The dose ranges to be evaluated in this', 'CYP2D6 genotyping', 'study, based on body weight and the', 'study, based on body weight and', 'adjusted to be', 'use of strong CYP2D6 inhibitors', 'CYP2D6 impairment status at baseline,', 'incorporated at', 'impairment status at baseline, were', 'were selected on the basis of the safety,', 'screening and by', 'selected on the basis of the safety,', 'preliminary efficacy, and population', 'CYP Impairment', 'preliminary efficacy, and population', 'pharmacokinetic data generated from', 'status', 'pharmacokinetic data generated from', 'Study SD-809-C-17 (Table 2).', 'Study SD-809-C-17 (Table 2 and Table', '3).', '1.8 Location and Study Duration', 'This study is planned to be conducted', 'This study is planned to be conducted', 'Study start date', 'in the North America, Russia, and', 'in North America, Russia, and Europe,', 'pushed out to', 'Europe, at approximately 50 centers. It', 'at approximately 50 centers. It is', 'January 2018, and', 'is expected to start in October 2017', 'expected to start in January 2018 and', 'Russia was specified', 'January 2018 and have a duration of', 'have a duration of approximately', 'as a location to be', 'approximately 15 months.', '15 months.', 'included for this', \"study's conduct.\", '137']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', '2.3.2 Key Secondary Efficacy Endpoint (Other sections affected by this change: 3.13 [Table 1]),', '9.5.2, 3.3.2', 'The key secondary efficacy endpoints', 'The key secondary efficacy endpoints', 'Adjusting of the Key', 'are as follows:', 'are as follows:', 'secondary efficacy', '1. Change in the TS-CGI score from', '1. Change in the TS-CGI score from', 'endpoint hierarchy.', 'baseline to week 12', 'baseline to week 12', 'was', '2. Change in the', '2. Change in the Tourette Syndrome-', 'removed, and placed', 'Patient Global Impression of Impact', 'as an exploratory', 'score from baseline to week', '(TS-PGII) score from baseline to', 'endpoint. TS-PGII', 'was inserted as the', '12 Change in the Tourette Syndrome-', 'week 12', 'Patient Global Impression of Impact', 'new (2) Secondary', '3. Change in the Child and', '(TS-PGII) score from baseline to', 'efficacy endpoint.', 'Adolescent Gilles de la Tourette', 'The child and', 'week 12', 'Syndrome - Quality of Life (C&A-', 'adolescent version of', '3. Change in the Child and', 'GTS-QOL) activities of daily living', 'the GTS-QOL scale', 'Adolescent Gilles de la Tourette', '(ADL) subscale score from baseline to', 'is now being used to', 'Syndrome - Quality of Life (C&A-', 'week 12', 'assess the (3)', 'GTS-QOL) physical/activities of daily', 'secondary efficacy', 'living (ADL) subscale score from', 'endpoint.', 'baseline to week 12', '2.3.3 Exploratory Endpoints (Other sections affected by this change: 3.3.3 and 9.5.3)', 'Exploratory endpoints are as follows:', 'Exploratory endpoints are as follows:', 'was moved', '(removed as a', 'secondary efficacy', 'endpoint) and is now', 'included as an', 'exploratory endpoint.', '138']\n\n###\n\n", "completion": "END"}